Get the Stockscreener App
14.72
0.81%
-0.12
Eyepoint Inc stock is traded at $14.72, with a volume of 1.64M.
It is down -0.81% in the last 24 hours and up +19.38% over the past month.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
See More
Previous Close:
$14.84
Open:
$14.8
24h Volume:
1.64M
Relative Volume:
1.46
Market Cap:
$1.23B
Revenue:
$7.62M
Net Income/Loss:
$-271.60M
P/E Ratio:
-4.2036
EPS:
-3.5018
Net Cash Flow:
$-271.54M
1W Performance:
+5.29%
1M Performance:
+19.38%
6M Performance:
-9.30%
1Y Performance:
+33.09%
1-Day Range:
$13.89
$14.80
1-Week Range:
$13.40
$14.99
52-Week Range:
$9.40
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Name
Eyepoint Inc
Sector
Industry
Phone
617-926-5000
Address
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
14.72 | 1.23B | 7.62M | -271.60M | -271.54M | -3.5018 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-17-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-07-25 | Initiated | Citigroup | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-22-24 | Initiated | JP Morgan | Overweight |
| Nov-02-23 | Initiated | Mizuho | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Jul-07-22 | Initiated | Chardan Capital Markets | Buy |
| Mar-01-21 | Initiated | Cowen | Outperform |
| Jan-28-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Nov-04-19 | Resumed | Laidlaw | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
View All
Eyepoint Inc Stock (EYPT) Latest News
Does EyePoint’s (EYPT) Broad Russell Index Debut Quietly Recast Its DURAVYU‑Centric Investor Base? - simplywall.st
ETFs Investing in EyePoint, Inc. Stocks - TradingView
EyePoint Pharmaceuticals updates its strategy as retinal pipeline advances - ad-hoc-news.de
EyePoint Pharmaceuticals Coverage Assumed by Cantor Fitzgerald at Overweight - Moomoo
EyePoint (EYPT) 44th Annual J.P. Morgan Healthcare Conference Summary - Quartr
Price to sales forward of EyePoint, Inc. – FWB:PV3B - TradingView
Here’s Why EyePoint, Inc. (EYPT) Is Among the Best Get Rich Quick Stocks - Insider Monkey
Price-Driven Insight from (EYPT) for Rule-Based Strategy - Stock Traders Daily
EyePoint shared additions to scientific advisory board and conditional approval of trade name for EYP-1901 - Ophthalmology Times Europe
Price to sales forward of EyePoint, Inc. – DUS:PV3B - TradingView
Price to earnings forward of EyePoint, Inc. – DUS:PV3B - TradingView
Guggenheim reiterates Buy on EyePoint stock, cites trial progress - Investing.com
EyePoint Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
EyePoint Pharmaceuticals outlines long-term retina strategy as a specialty biotech - ad-hoc-news.de
EYPTEyePoint Inc Forecast, Target Price - Finviz
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock By Investing.com - Investing.com South Africa
EyePoint CMO Ramiro Ribeiro sells $73,166 in company stock - Investing.com
Form 4 Eyepoint Pharmaceuticals Inc For: 2 July By Investing.com - Investing.com Canada
EyePoint CMO sells 4,875 shares after option exercise | EYPT Insider Trading - Stock Titan
EYPT Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Deceleration Risk - dars.gov.et
Spruce Street Capital LP's EyePoint Inc(EYPT) Holding History - GuruFocus
EYPT Rated Buy by Chardan Capital -- Price Target Raised to $65. - GuruFocus
Did Broad Russell Growth Index Additions Just Reframe EyePoint’s (EYPT) Small-Cap Biotech Profile? - Sahm
Chardan Boosts Price Target on EyePoint Pharmaceuticals to $65 From $29, Keeps Buy Rating - marketscreener.com
Huge - Moomoo
Chardan Capital Maintains EyePoint(EYPT.US) With Buy Rating, Raises Target Price to $65 - Moomoo
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Small Cap Comp Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2500 Growth Benchmark - marketscreener.com
Pivotal Clinical Trial Readouts On The Horizon; Keeping An Eye On EyePoint? - RTTNews
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 2000 Growth Benchmark - marketscreener.com
Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could - The Motley Fool
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell 3000E Growth Benchmark - marketscreener.com
EyePoint, Inc.(NasdaqGM: EYPT) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
EyePoint, Inc. Actuals & Estimates (NASDAQ:EYPT) - TradingView
Price to book forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to book forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EYPT Forecast — Price Target — Prediction for 2027 - TradingView
EyePoint, Inc. Actuals & Estimates (DUS:PV3B) - TradingView
EYPT Q1 2026 Earnings: Wider-Than-Expected Loss Weighs on SharesGAAP Earnings Report - dars.gov.et
(EYPT) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Price to sales forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Inc (EYPT) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Enterprise value to revenue forward of EyePoint, Inc. – NASDAQ:EYPT - TradingView
Price to earnings forward of EyePoint, Inc. – LS:A2QJRU - TradingView
A2QJRU Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of EyePoint, Inc. – LS:A2QJRU - TradingView
EyePoint Pharmaceuticals Inc (EYPT) Institutional Confidence - TradingKey
Guggenheim Maintains EyePoint(EYPT.US) With Buy Rating, Maintains Target Price $68 - Moomoo
EYPT Reiterated by Guggenheim -- Price Target Maintained at $68. - GuruFocus
Mizuho reiterates EyePoint stock rating on competitor timeline shift By Investing.com - Investing.com South Africa
Eyepoint Inc Stock (EYPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):